Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib and MK-2206 in BRAF-Mutant Advanced Melanoma
NCT01519427Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2012
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib, MK-2206 in melanoma, sponsored by National Cancer Institute. Started Jan 2012; status: terminated.
02
Drugs
selumetinibMK-2206
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01519427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01519427.